论文部分内容阅读
目的探讨参麦注射液治疗慢性阻塞性肺疾病(COPD)急性加重合并呼吸衰竭患者的临床疗效及安全性。方法选取2013年3月至2015年3月东莞市第八人民医院收治的86例COPD急性加重合并呼吸衰竭患者为研究对象,按随机数字表法将其分为对照组和观察组,各43例。对照组患者采用常规药物对症治疗,观察组患者在对照组基础上静脉滴注参麦注射液,比较两组患者的临床疗效、白细胞(WBC)计数、中性粒细胞(N)计数、红细胞沉降率(ESR)、C反应蛋白(CRP)、p H、动脉氧分压(Pa O2)、动脉二氧化碳分压(Pa CO2)水平。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后,观察组患者的WBC、N、CRP、ESR值均明显低于对照组,差异均有统计学意义(均P<0.05);治疗后,观察组患者的Pa O2水平明显高于对照组,Pa CO2水平明显低于对照组,差异均有统计学意义(均P<0.05)。结论参麦注射液辅助治疗COPD急性加重合并呼吸衰竭患者临床疗效明显,可有效改善患者的临床症状。
Objective To investigate the clinical efficacy and safety of Shenmai injection in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) and respiratory failure. Methods Eighty-six patients with acute exacerbation of COPD and respiratory failure admitted to the Eighth People’s Hospital of Dongguan City from March 2013 to March 2015 were selected as study subjects and divided into control group and observation group according to random number table method, 43 cases in each group . Patients in the control group were given symptomatic treatment with conventional drugs. The patients in the observation group were given intravenous infusion of Shenmai injection on the basis of the control group. The clinical efficacy, WBC count, neutrophil count (N), erythrocyte sedimentation rate ESR, CRP, p H, Pa O2 and PaCO2. Results The total effective rate of observation group was significantly higher than that of the control group (P <0.05). After treatment, the WBC, N, CRP and ESR of the observation group were significantly lower than those of the control group (All P <0.05). After treatment, PaO2 level in observation group was significantly higher than that in control group, and PaO2 level was significantly lower than that in control group (all P <0.05). Conclusion Shenmai injection in the treatment of acute exacerbation of COPD with respiratory failure patients with significant clinical efficacy, which can effectively improve the clinical symptoms of patients.